Glucagon‐like peptide‐1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta‐analysis and meta‐regression
Authors' conclusion
Patients on GLP-1RA experienced modest SBP lowering compared with placebo. This observed effect was associated with weight/body mass index reduction and better glycaemic control, which suggests that BP-lowering is an indirect effect of GLP-1RA and unlikely to be responsible for the benefits.
Study context
- Population
- Placebo-controlled RCTs of GLP-1 RA treatment, patients with and without DM; search until December 2023
- Comparison
- GLP-1 RAs vs placebo
- Outcome
- MD in systolic BP (SBP) and diastolic BP
Methodological detailsplacebo-controlled RCTs, random effects model, meta-regression, subgroup analyses
- Placebo-controlled RCTs
- Random effects model
- Meta-regression
- Subgroup analyses
Pooled result
As reported in the abstract
SBP
Each group vs placeboMD, mmHg (95% CI)P value
Semaglutide
−3.40(−4.22 to −2.59)
P < 0.001Liraglutide
−2.61(−3.48 to −1.74)
P < 0.001Dulaglutide
−1.46(−2.20 to −0.72)
P < 0.001Exenatide
−3.36(−3.63 to −3.10)
P < 0.001Further pooled results
| Outcome | MD (mmHg) (95% CI) | P value | |
|---|---|---|---|
| Diastolic BPExenatidevs Placebo | −0.94 (−1.78 to −0.1) | P = 0.03 | |
| −2−101Difference, mmHg (linear scale) |
Diastolic blood pressure (BP)
- Diastolic BP reduction significant only with exenatide
Meta-regression in semaglutide cohorts
- Mean changes in HbA1c and BMI directly associated with systolic BP (SBP) reduction
Original publication
Glucagon‐like peptide‐1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta‐analysis and meta‐regression. Diabetes Obes Metab. Published 20 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →